Cagrilintide (10mg) Nova 9 Peptides Premium Research Peptides Supplier CagriSema vs Tirzepatide: 23% Weight Loss in Phase 3 Trial Cagrilintide is an amylin analogue that helps regulate appetite. In a randomized trial of over 3400 patients who were overweight or obese and had 1 weight related complication, individuals assigned to a combination 1 CagriSema 2.4 mg 2.4 mg FDA NDA filing; Novo Nordisk data on file., 2 Garvey WT, Blher M, Osorto Contreras CK, et al. Coadministered cagrilintide and semaglutide in adults with overweight or Novo Nordisk Stock Rises on Trial Results for Cagrilintide Obesity Treatment Structural and dynamic features of cagrilintide binding to calcitonin and amylin receptors Nature Communications